Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ralimetinib + Gemcitabine/Carboplatin in Platinum-Sensitive Ovarian Cancer
NCT01663857Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2012
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ralimetinib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Tolerated Dose and Progression-Free Survival up to 3 years. Started Jul 2012; status: completed.
02
Drugs
ralimetinib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01663857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01663857.